INTERVENTION 1:	Intervention	0
Zoledronic Acid 4 mg Upfront	Intervention	1
zoledronic acid	CHEBI:46557	0-15
Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.	Intervention	2
acid	CHEBI:37527	12-16
minute	UO:0000031	42-48
day	UO:0000033	98-101
day	UO:0000033	152-155
day	UO:0000033	181-184
letrozole	CHEBI:6413	127-136
INTERVENTION 2:	Intervention	3
Zoledronic Acid 4 mg Delayed	Intervention	4
zoledronic acid	CHEBI:46557	0-15
Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.	Intervention	5
acid	CHEBI:37527	12-16
minute	UO:0000031	42-48
hip	UBERON:0001464	178-181
month	UO:0000035	66-71
month	UO:0000035	271-276
letrozole	CHEBI:6413	309-318
day	UO:0000033	334-337
day	UO:0000033	363-366
Inclusion Criteria:	Eligibility	0
Stage I-IIIa breast cancer	Eligibility	1
breast cancer	DOID:1612	13-26
Postmenopausal or recently postmenopausal	Eligibility	2
Recent surgery for breast cancer	Eligibility	3
surgery	OAE:0000067	7-14
breast cancer	DOID:1612	19-32
Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status	Eligibility	4
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
receptor	BAO:0000281	47-55
receptor	BAO:0000281	73-81
progesterone	CHEBI:17026	34-46
hormone	CHEBI:24621	65-72
No prior treatment with letrozole	Eligibility	5
letrozole	CHEBI:6413	24-33
Other protocol-defined inclusion criteria may apply.	Eligibility	6
Exclusion Criteria:	Eligibility	7
Metastatic disease	Eligibility	8
disease	DOID:4,OGMS:0000031	11-18
Invasive bilateral disease	Eligibility	9
bilateral	HP:0012832	9-18
disease	DOID:4,OGMS:0000031	19-26
Clinical or radiological evidence of existing fracture in spine or hip	Eligibility	10
hip	UBERON:0001464	67-70
Prior treatment with IV bisphosphonates in the past 12 months	Eligibility	11
Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)	Eligibility	12
Use of Tibolone within 6 months	Eligibility	13
tibolone	CHEBI:32223	7-15
Prior use of parathyroid hormone for more than 1 week	Eligibility	14
hormone	CHEBI:24621	25-32
week	UO:0000034	49-53
Previous or concomitant malignancy	Eligibility	15
Abnormal renal function	Eligibility	16
function	BAO:0003117,BFO:0000034	15-23
History of disease effecting bone metabolism	Eligibility	17
history	BFO:0000182	0-7
disease	DOID:4,OGMS:0000031	11-18
Other protocol-defined exclusion criteria may apply.	Eligibility	18
Outcome Measurement:	Results	0
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.	Results	1
bone mineral density	CMO:0001226	21-41
Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).	Results	2
bone mineral density	CMO:0001226	0-20
Time frame: Baseline, 12 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Zoledronic Acid 4 mg Upfront	Results	5
zoledronic acid	CHEBI:46557	17-32
Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.	Results	6
acid	CHEBI:37527	35-39
minute	UO:0000031	65-71
day	UO:0000033	121-124
day	UO:0000033	175-178
day	UO:0000033	204-207
letrozole	CHEBI:6413	150-159
Overall Number of Participants Analyzed: 423	Results	7
Mean (Standard Deviation)	Results	8
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: Percentage change in BMD  2.208         (3.4194)	Results	9
Results 2:	Results	10
Arm/Group Title: Zoledronic Acid 4 mg Delayed	Results	11
zoledronic acid	CHEBI:46557	17-32
Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.	Results	12
acid	CHEBI:37527	35-39
minute	UO:0000031	65-71
hip	UBERON:0001464	201-204
month	UO:0000035	89-94
month	UO:0000035	294-299
letrozole	CHEBI:6413	332-341
day	UO:0000033	357-360
day	UO:0000033	386-389
Overall Number of Participants Analyzed: 418	Results	13
Mean (Standard Deviation)	Results	14
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: Percentage change in BMD  -3.617         (4.2151)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 133/525 (25.33%)	Adverse Events	1
Anaemia 1/525 (0.19%)	Adverse Events	2
Febrile neutropenia 1/525 (0.19%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Acute myocardial infarction 2/525 (0.38%)	Adverse Events	4
acute myocardial infarction	DOID:9408	0-27
Angina pectoris 3/525 (0.57%)	Adverse Events	5
angina pectoris	HP:0001681	0-15
Angina unstable 1/525 (0.19%)	Adverse Events	6
Aortic valve incompetence 1/525 (0.19%)	Adverse Events	7
valve	UBERON:0003978	7-12
Arrhythmia 0/525 (0.00%)	Adverse Events	8
arrhythmia	HP:0011675	0-10
Atrial fibrillation 1/525 (0.19%)	Adverse Events	9
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Atrioventricular block complete 0/525 (0.00%)	Adverse Events	10
atrioventricular block	HP:0001678,DOID:0050820	0-22
Cardiac arrest 0/525 (0.00%)	Adverse Events	11
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
Adverse Events 2:	Adverse Events	12
Total: 124/535 (23.18%)	Adverse Events	13
Anaemia 1/535 (0.19%)	Adverse Events	14
Febrile neutropenia 0/535 (0.00%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Acute myocardial infarction 0/535 (0.00%)	Adverse Events	16
acute myocardial infarction	DOID:9408	0-27
Angina pectoris 2/535 (0.37%)	Adverse Events	17
angina pectoris	HP:0001681	0-15
Angina unstable 0/535 (0.00%)	Adverse Events	18
Aortic valve incompetence 1/535 (0.19%)	Adverse Events	19
valve	UBERON:0003978	7-12
Arrhythmia 1/535 (0.19%)	Adverse Events	20
arrhythmia	HP:0011675	0-10
Atrial fibrillation 4/535 (0.75%)	Adverse Events	21
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Atrioventricular block complete 1/535 (0.19%)	Adverse Events	22
atrioventricular block	HP:0001678,DOID:0050820	0-22
Cardiac arrest 2/535 (0.37%)	Adverse Events	23
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
